Neumora Therapeutics (NASDAQ:NMRA) and Big Cypress Acquisition (OTCMKTS:BCYP) Critical Survey

Neumora Therapeutics (NASDAQ:NMRA) and Big Cypress Acquisition (OTCMKTS:BCYP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, dividends, risk, earnings, valuation and institutional ownership.

Profitability

This table compares Neumora Therapeutics and Big Cypress Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-73.63%	-68.97%
Big Cypress Acquisition	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Neumora Therapeutics and Big Cypress Acquisition, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1	5	3	0	2.22
Big Cypress Acquisition	0	0	0	0	0.00

Neumora Therapeutics presently has a consensus target price of $9.29, suggesting a potential upside of 1,096.30%. Given Neumora Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Neumora Therapeutics is more favorable than Big Cypress Acquisition.

Insider & Institutional Ownership

47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 60.2% of Big Cypress Acquisition shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Neumora Therapeutics and Big Cypress Acquisition”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$235.93 million	($1.53)	-0.51
Big Cypress Acquisition	N/A	N/A	-$10,000.00	N/A	N/A

About Neumora Therapeutics

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

About Big Cypress Acquisition

Big Cypress Acquisition Corp. does not have significant operations. The company intends to acquire assets and businesses through a merger, capital stock exchange, stock purchase, reorganization, or similar business combination. It primarily focuses in the life science sector. The company was incorporated in 2020 and is based in Miami Beach, Florida.